FN3K and type 2 diabetes mellitus: The enzyme fructosamine-3-kinase (FN3K), which is known for deglycating hemoglobin (20), preventing micro- and macrovascular complications in type 2 diabetes mellitus (T2DM) (45), and macular degeneration by deglycating advanced glycation end products (AGEs) (46), also exhibits potential need for a therapeutic intervention.